1. 标的：NASDAQ: TLSA (目前6.99)
Tiziana Life Sciences PLC
这不是特斯拉！
这不是特斯拉！
这不是特斯拉！
很重要说三遍～
2. 分类：拉回6.5以下多，目标12～15
3. 分析/正文：
—Seeking Alpha:
Tiziana Life SciencesNASDAQ:TLSA)oars 48%remarket on the heels ofubmitting a patent applicationor the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 alone or in combination with other anti-viral drugs.
The company has a worldwide exclusive license for nasal administration of Foralumab and other anti-CD3 mAbs for the treatment of neurodegenerative and other diseases.
Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of regulatory T-cells.
4. 进退场机制：-15%